To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).

This is a phase II, multicenter, single-arm study in which the efficacy and safety of X-396 capsule (Ensartinib) will be assessed in adult Chinese patients with ROS1-positive (rearrangement or inversion) non-small cell lung cancer (NSCLC). Approximately 69 patients (59 for never-treated, and 10 for previously treated with crizotinib) with locally advanced or metastatic NSCLC carrying ROS1-rearrangement will be enrolled in the study.

Inclusion Criteria:

• Female or male, 18 years of age or older
• Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic
• Positive for translocation or inversion events involving the ROS1 gene
• Tyrosine kinase inhibitor (TKI) treatment-naive or have previously received no more than one systemic treatment regimen(s) such as chemotherapy (After a 3-week washout period)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
• Predicted survival ≥ 3 months
• Drug related toxicities were relieved to grade 1, except for hair loss (based on NCI CTCAE v4.03)
• Adequate organ function
• At least 1 measurable tumor lesion as per RECIST v1.1
• Asymptomatic central nervous system (CNS) metastases do not require the use of steroids or anticonvulsants.
• Signed and dated informed consent
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
• Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment

Exclusion Criteria:

• Current treatment on another systemic anti-cancer therapy
• Prior therapy specifically directed against ROS1 fusion genes (except for the exploratory arm that will enroll patients pretreated with crizotinib)
• Evidence of active malignancy within last 3 years
• Previous therapeutic clinical trial must have completed at least 4 week prior to initiation of study drug
• Prior surgery or immunotherapy must have completed at least 4 weeks, and radiation must have been completed at least 2 weeks prior to initiation of study drug
• Known interstitial fibrosis or interstitial lung disease
• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medication
• Clinically significant cardiovascular disease
• Patients with a known allergy or delayed hypersensitivity reaction to study drug or its excipient
• Pregnant or breast feeding
• Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers
• Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
• Other serious illness or medical condition potentially interfering with the study